Urogen Pharma Inc.

Urogen Pharma Inc. is a for-profit pharmaceutical company headquartered in Princeton, New Jersey, that specializes in providing specialized oncological treatments to the U.S. Department of Veterans Affairs. Registered in SAM.gov since March 3, 2020, the company has established itself as a key supplier of innovative cancer pharmaceuticals to the VA healthcare system. Urogen Pharma Inc. has secured federal contract vehicles and maintains an active presence as a prime federal contractor, delivering specialized pharmaceutical products across multiple Veterans Integrated Service Networks nationwide.

Urogen Pharma Inc. has provided two primary pharmaceutical products through its federal contract awards: JELMYTO (mitomycin) and Zusduri (mitomycin). JELMYTO, an antineoplastic antibiotic treatment for low-grade upper tract urothelial cancer, represents the company's primary product offering to the VA, with multiple delivery orders awarded across Veterans Integrated Service Networks 5, 20, 21, and 22 between June 2023 and April 2025. These delivery orders have ranged in value from approximately $97,430 to $204,528, with ceiling values structured as firm fixed-price contracts. More recently, in December 2025, Urogen Pharma Inc. received a delivery order from Veterans Integrated Service Network 6 for Zusduri medication, valued at $32,844.22, reflecting the company's expansion of specialized cancer treatment offerings to the VA. All contract awards have been issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) with no set-aside designations applied, indicating awards made through full and open competition. The Department of Veterans Affairs, through its various regional networks and the National Acquisition Center, has served as the exclusive funding agency for all identified contract awards. Performance locations have included Dublin, Ohio; La Vergne, Tennessee; and Princeton, New Jersey, demonstrating the company's national distribution capabilities.

Urogen Pharma Inc. holds a single-award Blanket Purchase Agreement valued at $2.5 million, established on March 1, 2021, and extending through February 28, 2026. This indefinite delivery vehicle, awarded by the National Acquisition Center, operates under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and provides pre-negotiated procurement mechanisms for JELMYTO kits and JELMYTO mitomycin products across the VA's healthcare network. The BPA structure enables multiple Veterans Integrated Service Networks to issue delivery orders efficiently without conducting individual full and open competitions for each procurement action, establishing standardized pricing and terms that support the VA's responsive procurement of specialized cancer treatments. The contract ceiling of $2.5 million provides budgetary predictability while maintaining the flexibility required to meet clinical demand across geographically dispersed VA facilities. This indefinite delivery vehicle has facilitated the delivery orders identified in the company's recent award history and provides a streamlined framework for continued pharmaceutical procurement by the VA system through early 2026.